Immunovant Inc
IMVTHealthcare|Biotechnology|USA
$39.71
-1.38 (-3.36%)
Tangible Book
$4.18
Earnings Power
$4.41
Financials
Financial Snapshot
Market Cap
$8.15B
Enterprise Value
$902.0M
Revenue (TTM)
$0.00
Net Income (TTM)
$-505.6M
Cash & Equivalents
—
Net Cash/Share
$3.91
Free Cash Flow (TTM)
$-407.3M
Operating CF (TTM)
$-407.3M
Debt/Equity
0
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$101.8M
Monthly Burn
$33.9M
Est. Runway
—
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $325.0K | $100.6M | $400.1M | $493.8M | $376.5M | $635.4M | $714.0M | $902.1M | $902.1M | |
| Operating Cash Flow | $0.00 | $-53.4M | $-83.3M | $-106.1M | $-188.2M | $-214.2M | $-375.9M | $-407.3M | $-407.3M | |
| Free Cash Flow | $0.00 | $-53.4M | $-83.5M | $-106.4M | $-188.4M | $-214.6M | $-376.6M | $-407.3M | $-407.3M | |
| Capital Expenditure | $0.00 | $-31.0K | $-210.0K | $-254.0K | $-197.0K | $-360.0K | $-759.0K | $-8.0K | $0.00 | |
| Financing Cash Flow | $0.00 | $147.0M | $383.1M | $200.1M | $70.9M | $472.4M | $454.5M | $595.8M | $595.8M |
R&D Spending
R&D (TTM)
$456.7M
R&D Intensity
—
R&D Growth YoY
+0.0%
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $47.9M | $68.6M | $101.8M | $160.3M | $212.9M | $360.9M | $456.7M | $456.7M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | |
| SG&A | $0.00 | $18.2M | $39.5M | $54.2M | $48.0M | $57.3M | $77.2M | $76.2M | $76.2M |
Income Statement
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $0.00 | $47.9M | $68.6M | $101.8M | $160.3M | $212.9M | $360.9M | $456.7M | $456.7M | |
| SG&A | $0.00 | $18.2M | $39.5M | $54.2M | $48.0M | $57.3M | $77.2M | $76.2M | $76.2M | |
| Operating Income | $0.00 | $-66.1M | $-108.1M | $-156.0M | $-208.3M | $-270.2M | $-438.2M | $-532.9M | $-532.9M | |
| Interest Expense | $0.00 | $-625.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $0.00 | $-66.3M | $-107.8M | $-156.8M | $-211.0M | $-258.8M | $-412.9M | $-505.4M | $-505.4M | |
| Net Income | $0.00 | $-66.4M | $-107.4M | $-156.7M | $-211.0M | $-259.3M | $-413.8M | $-505.6M | $-505.6M | |
| EPS (Diluted) | 0.00 | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | -2.77 | -2.78 | |
| EBITDA | $0.00 | $-65.6M | $-108.1M | $-155.9M | $-208.1M | $-270.0M | $-437.8M | $-532.5M | $-532.5M | |
| Shares Out. (M) | - | 43.20 | 87.76 | 109.68 | 123.08 | 138.10 | 151.57 | 182.42 | 203.44 |
Balance Sheet
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $325.0K | $100.6M | $400.1M | $493.8M | $376.5M | $635.4M | $714.0M | $902.1M | $902.1M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $325.0K | $109.1M | $409.0M | $512.9M | $404.3M | $665.8M | $767.7M | $948.8M | $948.8M | |
| Total Assets | $405.0K | $109.4M | $412.5M | $515.6M | $405.8M | $666.4M | $776.2M | $957.0M | $957.0M | |
| Total Current Liabilities | $380.0K | $15.3M | $18.8M | $44.5M | $43.3M | $48.6M | $68.8M | $104.4M | $104.4M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $380.0K | $15.3M | $21.0M | $45.7M | $43.3M | $48.6M | $68.8M | $104.4M | $104.4M | |
| Stockholders' Equity | $25.0K | $94.1M | $391.5M | $469.8M | $362.5M | $617.8M | $707.4M | $852.6M | $852.6M | |
| Retained Earnings | $0.00 | $-91.2M | $-198.7M | $-355.4M | $-566.3M | $-825.7M | $-1.24B | $-1.75B | $-1.75B |
Cash Flow Statement
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $-53.4M | $-83.3M | $-106.1M | $-188.2M | $-214.2M | $-375.9M | $-407.3M | $-407.3M | |
| Capital Expenditure | $0.00 | $-31.0K | $-210.0K | $-254.0K | $-197.0K | $-360.0K | $-759.0K | $-8.0K | $0.00 | |
| Free Cash Flow | $0.00 | $-53.4M | $-83.5M | $-106.4M | $-188.4M | $-214.6M | $-376.6M | $-407.3M | $-407.3M | |
| Investing Cash Flow | $0.00 | $-31.0K | $-210.0K | $-254.0K | $-197.0K | $-360.0K | $-759.0K | $-8.0K | $-8.0K | |
| Financing Cash Flow | $0.00 | $147.0M | $383.1M | $200.1M | $70.9M | $472.4M | $454.5M | $595.8M | $595.8M | |
| Issuance of Stock | $0.00 | $0.00 | $319.8M | $0.00 | $70.5M | $472.7M | $450.0M | $544.2M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $42.9M | $3.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $-5.0M | $-6.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $7.0M | $18.8M | $34.2M | $32.3M | $41.1M | $49.5M | $55.7M | $55.7M | |
| Net Change in Cash | $0.00 | $93.6M | $299.6M | $93.7M | $-117.3M | $258.8M | $78.6M | $188.1M | $188.1M |
Dilution Tracker
Shares outstanding grew 85.5% over 5 years — significant dilution
Shares Outstanding
203M
5-Year Share Growth
+85.5%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | - | 43.20 | 87.76 | 109.68 | 123.08 | 138.10 | 151.57 | 182.42 | 203.44 | |
| YoY Change % | — | — | 103.1% | 25.0% | 12.2% | 12.2% | 9.8% | 20.4% | 11.5% | |
| Stock Issuance | $0.00 | $0.00 | $319.8M | $0.00 | $70.5M | $472.7M | $450.0M | $544.2M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $7.0M | $18.8M | $34.2M | $32.3M | $41.1M | $49.5M | $55.7M | $55.7M |
Margins & Profitability
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | -141.1% | -44.3% | -36.4% | -50.7% | -52.9% | -62.5% | -64.8% | -68.8% | |
| ROA % | 0.0% | -120.9% | -41.2% | -33.8% | -45.8% | -48.4% | -57.4% | -58.3% | -62.7% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S—
Historical— / — / —
Industry Med.9.51
P/B9.50
Historical— / — / 9.50
Industry Med.2.93
EV/EBITDA-13.62
Historical-13.62 / — / —
Industry Med.13.14
EV/Revenue—
Historical— / — / —
Industry Med.8.71
P/FCF—
Historical— / — / —
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$4.18
Net Current Assets
$4.140
Net-Net Working Capital
$3.92
| Metric | Trend | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 9.04 | 4.01 | 1.37 | 5.58 | 7.61 | 4.11 | 5.94 | 9.50 | |
| EV/EBITDA | 0.00 | -11.43 | -10.87 | -0.96 | -7.91 | -15.07 | -5.01 | -7.82 | -13.62 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
2
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $49.39M | $509.06M |
| Net Income | $-559.43M | $-611.29M | $-377.04M |
| EPS | -2.66 | -2.78 | -1.66 |
| Book Value per Share | 4.29 | 4.08 | 3.78 |
| Operating Cash Flow per Share | -2.01 | -1.58 | -0.50 |
| Operating CF | $-409.59M | $-321.44M | $-101.72M |